15.80
price down icon5.45%   -0.91
after-market Handel nachbörslich: 15.49 -0.31 -1.96%
loading

Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten

pulisher
Mar 12, 2026

Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - Yahoo Finance

Mar 12, 2026
pulisher
Mar 12, 2026

Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Mar 12, 2026
pulisher
Mar 10, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 10, 2026
pulisher
Mar 07, 2026

Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World

Mar 07, 2026
pulisher
Mar 06, 2026

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail

Mar 06, 2026
pulisher
Mar 02, 2026

Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan

Mar 02, 2026
pulisher
Feb 27, 2026

Millennium Management LLC Acquires Additional Shares in Avalo Th - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

AVTX Should I Buy - Intellectia AI

Feb 26, 2026
pulisher
Feb 25, 2026

Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView

Feb 25, 2026
pulisher
Feb 24, 2026

TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa

Feb 24, 2026
pulisher
Feb 24, 2026

Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - MSN

Feb 24, 2026
pulisher
Feb 24, 2026

TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity By Investing.com - Investing.com South Africa

Feb 24, 2026
pulisher
Feb 24, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences - Bitget

Feb 24, 2026
pulisher
Feb 23, 2026

Patient Square Capital LP Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat

Feb 23, 2026
pulisher
Feb 22, 2026

AVTXAvalo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 22, 2026

Aberdeen Group plc Makes New $925,000 Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat

Feb 22, 2026
pulisher
Feb 21, 2026

Reviewing Avalo Therapeutics (NASDAQ:AVTX) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2026
pulisher
Feb 20, 2026

Balyasny Asset Management L.P. Reduces Stake in Avalo Therapeuti - GuruFocus

Feb 20, 2026
pulisher
Feb 18, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 18, 2026
pulisher
Feb 17, 2026

Millennium discloses 4.8% Avalo Therapeutics (AVTX) ownership position - Stock Titan

Feb 17, 2026
pulisher
Feb 13, 2026

Can Avalo Therapeutics Inc. outperform under higher oil pricesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

Is Avalo Therapeutics Inc. stock overvalued by current metricsJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

How Avalo Therapeutics Inc. stock reacts to global recession fearsWeekly Stock Recap & Community Shared Stock Ideas - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 13, 2026
pulisher
Feb 11, 2026

Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

What analysts say about Avalo Therapeutics Inc. stockJuly 2025 Breakouts & AI Driven Price Forecasts - mfd.ru

Feb 11, 2026
pulisher
Feb 10, 2026

SilverArc Capital and Devesh Gandhi report 2.83% Avalo Therapeutics (AVTX) holding - Stock Titan

Feb 10, 2026
pulisher
Feb 06, 2026

Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 05, 2026

Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail

Feb 05, 2026
pulisher
Feb 04, 2026

Avalo Therapeutics shares jump as Guggenheim starts coverage with buy - MSN

Feb 04, 2026
pulisher
Feb 04, 2026

Biotech firm Avalo will stream two investor talks in February - Stock Titan

Feb 04, 2026
pulisher
Feb 02, 2026

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim Initiates Coverage on Avalo Therapeutics (AVTX) with - GuruFocus

Feb 02, 2026
pulisher
Feb 02, 2026

Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating By Investing.com - Investing.com Australia

Feb 02, 2026
pulisher
Feb 02, 2026

Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy - Investing.com UK

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy By Investing.com - Investing.com India

Feb 02, 2026
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):